Resources from the same session
135O - A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced MIBC
Presenter: Feng Wen
Session: Proffered Paper session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
157O - Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Fred Saad
Session: Proffered Paper session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 135O and 157O
Presenter: Enrique Grande Pulido
Session: Proffered Paper session: Genitourinary tumours
Resources:
Slides
Webcast